Study of nasal exosomes for early-onset Alzheimer's disease
Part of Brain & nervous system, Mental health clinical trials.
This study tests a new treatment using tiny particles from stem cells (called exosomes) given as a nasal spray. It aims to see if it can help people with early-onset Alzheimer's disease, which starts before age 65.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 50 and 75 years old.
- You have been diagnosed with Alzheimer's disease, and your symptoms started before age 65.
- Your memory and thinking problems are moderate to severe.
- You have a positive PET scan showing amyloid plaques in the brain (a hallmark of Alzheimer's).
- You have a caregiver who can come with you to visits and help with assessments.
- You are on stable medications for memory or mood for at least 2 months, if any.
- You have completed at least primary school and can do cognitive tests.
- You do not have other major health issues like severe heart disease, cancer, or immune disorders.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug made from stem cell exosomes (CB-Exo-A600) to see if it can help people with mild to moderate Alzheimer's disease. It aims to slow down symptoms and improve quality of life.
This trial tests a stem cell treatment for people with early-stage Alzheimer's disease. It aims to see if the treatment can help slow memory loss or other symptoms. You must have a specific blood test showing inflammation in the body to qualify.
This trial tests a new nasal spray called NeuroEPO to see if it is safe and helps people with mild to moderate Alzheimer's disease. The study aims to improve memory and daily functioning.
This study looks at a specific brain pathway that may be linked to early memory loss in Alzheimer's disease. It compares people with early Alzheimer's to healthy older adults to understand how connections between brain cells start to break down.
This study looks for brain/biological “signals” (biomarkers) that may identify Alzheimer’s disease earlier, including stages before clear symptoms. You may be followed for about 5 years, with repeated memory and thinking testing to see how these signs relate to future diagnosis.
This study looks at how to better predict and understand Alzheimer's disease by using advanced brain scans and spinal fluid tests. It aims to find ways to identify people who stay healthy longer despite risk factors.
Hear when a new Alzheimer Disease (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.